Patients with juvenile myelomonocytic leukemia due to germline CBL mutation (10% to 15%) may have a subacute course occasionally associated with autoimmune disorders, which may resemble RAS-associated autoimmune lymphoproliferative disorder. In both conditions, prognosis and standard treatment for autoimmune phenomena remain poorly understood. We report the case of a 7-year-old boy with juvenile myelomonocytic leukemia with severe steroid-dependent uveitis, who did not respond to several therapeutic attempts with immunosuppressant agents, including sirolimus, and was finally successfully treated with adalimumab. This case offers further insight into the management of autoimmune disorders in the context of predisposing genetic conditions.
*University of Trieste
†Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”
‡Institute for Maternal and Child Health, IRCCS “Burlo Garofolo,” University of Trieste, Trieste, Italy
The authors declare no conflict of interest.
Reprints: Luisa Cortellazzo Wiel, MD, Università degli Studi di Trieste, Piazzale Europa 1, Trieste 34127, Italia (e-mail:email@example.com).
Received November 3, 2018
Accepted January 10, 2019